Annex I Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)
1
Scientific conclusions Taking into account the PRAC Assessment Report on the PSUR(s) for ibuprofen / pseudoephedrine, the scientific conclusions are as follows: Based on review of literature data, the PRAC considered that a causal relationship between the use of ibuprofen / pseudoephedrine and the occurrence of severe skin reactions such as acute generalised exanthematous pustulosis (AGEP) could not be excluded and therefore requests an update of the product information of all ibuprofen / pseudoephedrine containing products in this regard. The Summary of Product Characteristics should be updated to insert a warning on the risk of severe skin reactions such as acute generalized exanthematous pustulosis and to list this adverse drug reaction with the frequency not known. The Package Leaflet should be updated accordingly. The CMDh agrees with the scientific conclusions made by the PRAC.
Grounds for the variation to the terms of the Marketing Authorisation(s) On the basis of the scientific conclusions for ibuprofen / pseudoephedrine the CMDh is of the opinion that the benefit-risk balance of the medicinal product(s) containing ibuprofen / pseudoephedrine is unchanged subject to the proposed changes to the product information. The CMDh reaches the position that the marketing authorisation(s) of products in the scope of this single PSUR assessment should be varied. To the extent that additional medicinal products containing ibuprofen / pseudoephedrine are currently authorised in the EU or are subject to future authorisation procedures in the EU, the CMDh recommends that that the concerned Member States and applicant/marketing authorisation holders take due consideration of this CMDh position.
Annex II Amendments to the product information of the nationally authorised medicinal product(s)
Amendments to be included in the relevant sections of the Product Information (new text underlined and in bold, deleted text strike through) Summary of Product Characteristics •
Section 4.4
A warning should be added as follows: Severe Skin reactions Severe skin reactions such as acute generalized exanthematous pustulosis (AGEP) may occur with pseudoephedrine-containing products. This acute pustular eruption may occur within the first 2 days of treatment, with fever, and numerous, small, mostly non-follicular pustules arising on a widespread oedematous erythema and mainly localized on the skin folds, trunk, and upper extremities. Patients should be carefully monitored. If signs and symptoms such as pyrexia, erythema, or many small pustules are observed, administration of should be discontinued and appropriate measures taken if needed. •
Section 4.8
The following adverse reaction should be added under the SOC Skin and subcutaneous tissue disorders with a frequency unknown: - Severe skin reactions, including acute generalized exanthematous pustulosis (AGEP)
Package Leaflet •
Section 2
Warnings and precautions If you develop a feverish generalised erythema associated with pustules, stop taking and contact your doctor or seek medical attention immediately. See section 4. •
Section 4
Frequency “Not known” Sudden onset of fever, reddening of the skin, or many small pustules (possible symptoms of Acute Generalized Exanthematous Pustulosis - AGEP) may occur within the first 2 days of treatment with . See section 2. Stop using if you develop these symptoms and contact your doctor or seek medical attention immediately.
Annex III Timetable for the implementation of this position
Timetable for the implementation of this position
Adoption of CMDh position:
February 2018 CMDh meeting
Transmission to National Competent Authorities
07 April 2018
of the translations of the annexes to the position : Implementation of the position by the Member States (submission of the variation by the Marketing Authorisation Holder):
5 days ago - with the frequency not known. The Package Leaflet should be updated accordingly. The CMDh agrees with the scientific conclusions made by the PRAC. Grounds for the variation to the terms of the Marketing Authorisation(s). On the basis of the scientific conclusions for ibuprofen / pseudoephedrine the ...
Oct 28, 2017 - Taking into account the PRAC Assessment Report on the PSUR(s) for levobunolol (ophthalmic indication), the scientific conclusions are as ...
Sep 2, 2017 - Summary of Product Characteristics. â¢. Section 4.8. The following adverse reactions should be added under the SOC âReproductive system and ...
Oct 28, 2017 - Taking into account the PRAC Assessment Report on the PSUR(s) for levobunolol (ophthalmic indication), the ... reactions should be included in the product information for levobunolol-containing products authorised ... indication) is un
Dec 23, 2017 - 2. Scientific conclusions. Taking into account the PRAC Assessment Report on the PSUR(s) for mefloquine, the scientific conclusions are as follows: ... Amendments to be included in the relevant sections of the Product Information (new
PASS to evaluate the effectiveness of the risk minimisation activities as imposed during ... Grounds for the variation to the terms of the Marketing Authorisation(s).
Mar 10, 2018 - Scientific conclusions. Taking into account the PRAC Assessment Report on the PSUR(s) for azithromycin (systemic use formulations), the scientific conclusions are as follows: In view of the increasing understanding on drug-drug interac
The joint database drug utilisation final study report submitted by the MAHs, together with the ... The MAH(s) should provide within the risk management plan.
Oct 29, 2016 - PRAC reviewed the available post marketing safety data, published ... The CMDh reaches the position that the marketing authorisation(s) of ...
Nov 25, 2017 - Taking into account the PRAC Assessment Report on the PSUR(s) for saccharomyces boulardii, the scientific ... patients is considered changed and an update of the product information is warranted. ... relevant sections of the SmPC (sect
Jul 1, 2017 - ... Report on the PSUR(s) for cetirizine / pseudoephedrine e, ... Grounds for the variation to the terms of the Marketing ... [The following adverse reaction should be added under the SOC Reproductive system and breast.
Apr 7, 2018 - **Uterine rupture has been uncommonly reported after prostaglandin intake during the second or third trimester of pregnancy. Uterine ruptures occurred particularly in multiparous women or in women with a caesarean section scar. Package
Dec 22, 2016 - Taking into account the PRAC Assessment Report on the PSUR(s) for granisetron ... Annex III. Timetable for the implementation of this position ...
Jun 9, 2018 - Based on a comprehensive review of âparaesthesiaâ, including ... of hypersensitivity reactions to chrysanthemums including literature ...
Aug 5, 2017 - Taking into account the PRAC Assessment Report on the PSUR(s) for ... for the variation to the terms of the Marketing Authorisation(s) ... Page 3 ...
Jun 9, 2018 - peak toxicity and prolonged recovery when compared to immediate-release (IR) quetiapine overdose: a retrospective cohort study. Clinical ...
Jun 4, 2017 - Grounds for the variation to the terms of the Marketing Authorisation(s). On the basis of the scientific conclusions for finasteride the CMDh is of ...
Mar 10, 2018 - trace residue from the manufacturing process), or to any of the excipients., or The the stopper of the glass vial with Actilyse powder which contains natural rubber (a derivative of latex). which may cause allergic reactions. No sustai
Dec 27, 2017 - for anxiety in one case and taking into account the listedness of these adverse reactions in the product information of other progestin only medicinal products, the lead member state considers that anxiety and depression should be incl
Aug 5, 2017 - colitis for proton pump inhibitors is relatively small and the number of ... Given the cases with positive de-challenge which clearly support the ...
Nov 25, 2017 - Allergic reactions the signs of which may include difficulty in breathing, dizziness, collapsing or losing consciousness, swelling of your face, lips ...
possible risks with exposure to non-steroidal anti-inflammatory drugs like diclofenac in pregnant women, in ... drugs with regard to use during pregnancy and risk of miscarriage and congenital malformations as agreed ... Women of childbearing potenti
27 Jan 2018 - Taking into account the PRAC Assessment Report on the PSUR(s) for lanthanum, the scientific ... this PSUR, the PRAC considers that the product information of lanthanum containing medicinal products should be ... Amendments to the produc